#mike doustdar

1 story

#business #eli lilly #finance #glp-1 #mergers and acquisitions #novo nordisk #pharmaceutical industry #wegovy #weight loss drugs

Novo CEO eyes M&A deals as weight-loss dominance slips
Novo Nordisk's turnaround plan failed to convince investors, prompting CEO Mike Doustdar to signal openness to acquisitions beyond obesity drugs.
CNBC · 2m